In vitro models of diabetes-related AD, glucagon-like peptide-1, which was created to treat Type 2 DM, greatly increased neuroprotection against advanced glycation end product-induced neuronal insult (Biswas et al., 2008; Abd El-Rady et al., 2021). The gene discussed is GCG; the disease is Alzheimer disease.